1-(3,5-diacetyl-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-urea | 475587-68-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3,5-diacetyl-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-urea
• 英文别名: 1-(3,5-Diacetylphenyl)-3-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]urea
• CAS: 475587-68-9
• 化学式: C₂₇H₂₄N₆O₃
• 分子量: 480.526
• InChiKey: DKVJUKLHDJSCGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(3,5-diacetyl-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-urea 、 氨基胍媒染剂 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 24.25h， 生成 1-(3,5-diacetyl-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-urea-bis-aminohydrazone
  参考文献：
  名称：

  Pyrimidine Derivatives

  摘要：

  本发明涉及嘧啶衍生物，其合成方法，以及所述嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗细胞增殖紊乱、癌症、白血病、勃起功能障碍、心血管疾病和紊乱、炎症性疾病、移植排斥、免疫性疾病、神经免疫性疾病、自身免疫性疾病、感染性疾病包括机会性感染、朊病和/或神经退行性疾病。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药用可接受盐作为活性成分的药物组合物，以及用于预防和/或治疗上述疾病和紊乱的方法。

  公开号：

  US20080187575A1
• 作为产物：
  描述：

  3,5-diacetyl aniline 、 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶 在 氯甲酸三氯甲酯 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 1-(3,5-diacetyl-phenyl)-3-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-urea
  参考文献：
  名称：

  Pyrimidine Derivatives

  摘要：

  本发明涉及嘧啶衍生物，其合成方法，以及所述嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗细胞增殖紊乱、癌症、白血病、勃起功能障碍、心血管疾病和紊乱、炎症性疾病、移植排斥、免疫性疾病、神经免疫性疾病、自身免疫性疾病、感染性疾病包括机会性感染、朊病和/或神经退行性疾病。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药用可接受盐作为活性成分的药物组合物，以及用于预防和/或治疗上述疾病和紊乱的方法。

  公开号：

  US20080187575A1

文献信息

• Pyridylpyrimidine derivatives as effective compounds against prion diseases
  申请人：——

  公开号：US20030176443A1

  公开（公告）日：2003-09-18

  The present invention relates to pyridylpyrimidine derivatives of the general formula (I): 1 wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD which can be inhibited by the inventive pyridylpyrimidine derivatives.

  本发明涉及一般式（I）的吡啶基嘧啶衍生物，其中R代表氢或甲基，Z代表含氮的功能基团，该吡啶基嘧啶衍生物作为药物活性剂的使用，特别是用于预防和/或治疗朊病毒感染和朊病，以及含有至少一种吡啶基嘧啶衍生物和/或其药学可接受的盐的组合物。此外，本发明还涉及使用所述吡啶基嘧啶衍生物预防和/或治疗朊病毒感染和朊病的方法。人类细胞蛋白激酶、磷酸酶和细胞信号转导分子被揭示为检测、预防和/或治疗朊病毒感染和疾病的靶点，特别是BSE、vCJD或CJD，这些疾病可以被本发明的吡啶基嘧啶衍生物抑制。
• Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
  申请人：GPC Biotech AG

  公开号：EP1721609A2

  公开（公告）日：2006-11-15

  The present invention relates to pyridylpyrimidine derivatives of the general formula (I): wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD which can be inhibited by the inventive pyridylpyrimidine derivatives.

  本发明涉及通式（I）的吡啶嘧啶衍生物： 其中 R 代表氢或甲基，Z 代表含氮官能团；吡啶嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗朊病毒感染和朊病毒疾病；以及含有至少一种吡啶嘧啶衍生物和/或其药学上可接受的盐的组合物。此外，本发明还涉及使用所述吡啶嘧啶衍生物预防和/或治疗朊病毒感染和朊病毒疾病的方法。本发明公开了人体细胞蛋白激酶、磷酸酶和细胞信号传导分子，作为检测、预防和/或治疗朊病毒感染和疾病的靶标，特别是可被本发明吡啶嘧啶衍生物抑制的 BSE、vCJD 或 CJD。
• PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES
  申请人：GPC Biotech AG

  公开号：EP1395261B1

  公开（公告）日：2006-06-28
• PYRIMIDINE DERIVATIVES
  申请人：GPC Biotech AG

  公开号：EP1786781A2

  公开（公告）日：2007-05-23
• [EN] PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES<br/>[FR] DERIVES DE PYRIDYLPYRIMIDINE UTILISES COMME COMPOSES ACTIFS CONTRE DES INFECTIONS ET DES MALADIES A PRIONS
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2002093164A2

  公开（公告）日：2002-11-21

  The present invention relates to pyridylpyrimidine derivatives of the general formula (I) : wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD, which can be inhibited by the inventive pyridylpyrimidine derivatives.